The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Allogeneic Universal Cell Drugs Market Research Report 2024

Global Allogeneic Universal Cell Drugs Market Research Report 2024

Publishing Date : Jan, 2024

License Type :
 

Report Code : 1893503

No of Pages : 108

Ask Your Query
Synopsis
Allogeneic universal cells, also called off-the-shelf cells, refer to a type of cell therapy that uses cells from different individuals instead of the patient's own cells for treatment.
The global Allogeneic Universal Cell Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Allogeneic Universal Cell Drugs is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Allogeneic Universal Cell Drugs is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Allogeneic Universal Cell Drugs include Novartis, Gilead Sciences, Yi Zun Biology, Bangyao Biotechnology, Usano, Cellectis, Allogene, Caribou and Poseida Therapeutics, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Allogeneic Universal Cell Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Allogeneic Universal Cell Drugs.
Report Scope
The Allogeneic Universal Cell Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Allogeneic Universal Cell Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Allogeneic Universal Cell Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Novartis
Gilead Sciences
Yi Zun Biology
Bangyao Biotechnology
Usano
Cellectis
Allogene
Caribou
Poseida Therapeutics
Keji Pharmaceutical
Beiheng Biotechnology
Grace Biotechnology
Nkarta Therapeutic
Fate Therapeutics
Ruishun Biology
Cynata
Fate
Century
Cytovia
BeiGene
Cell-Origin
Neukio
Segment by Type
CAR-T cell therapy
Natural Universal Cell Therapy
Immune Cell Therapy
Segment by Application
Hematoma
Solid Tumor
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Southeast Asia
China Taiwan
Australia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Allogeneic Universal Cell Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Allogeneic Universal Cell Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index
1 Allogeneic Universal Cell Drugs Market Overview
1.1 Product Overview and Scope of Allogeneic Universal Cell Drugs
1.2 Allogeneic Universal Cell Drugs Segment by Type
1.2.1 Global Allogeneic Universal Cell Drugs Market Value Comparison by Type (2024-2030)
1.2.2 CAR-T cell therapy
1.2.3 Natural Universal Cell Therapy
1.2.4 Immune Cell Therapy
1.3 Allogeneic Universal Cell Drugs Segment by Application
1.3.1 Global Allogeneic Universal Cell Drugs Market Value by Application: (2024-2030)
1.3.2 Hematoma
1.3.3 Solid Tumor
1.4 Global Allogeneic Universal Cell Drugs Market Size Estimates and Forecasts
1.4.1 Global Allogeneic Universal Cell Drugs Revenue 2019-2030
1.4.2 Global Allogeneic Universal Cell Drugs Sales 2019-2030
1.4.3 Global Allogeneic Universal Cell Drugs Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Allogeneic Universal Cell Drugs Market Competition by Manufacturers
2.1 Global Allogeneic Universal Cell Drugs Sales Market Share by Manufacturers (2019-2024)
2.2 Global Allogeneic Universal Cell Drugs Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Allogeneic Universal Cell Drugs Average Price by Manufacturers (2019-2024)
2.4 Global Allogeneic Universal Cell Drugs Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Allogeneic Universal Cell Drugs, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Allogeneic Universal Cell Drugs, Product Type & Application
2.7 Allogeneic Universal Cell Drugs Market Competitive Situation and Trends
2.7.1 Allogeneic Universal Cell Drugs Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Allogeneic Universal Cell Drugs Players Market Share by Revenue
2.7.3 Global Allogeneic Universal Cell Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Allogeneic Universal Cell Drugs Retrospective Market Scenario by Region
3.1 Global Allogeneic Universal Cell Drugs Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Allogeneic Universal Cell Drugs Global Allogeneic Universal Cell Drugs Sales by Region: 2019-2030
3.2.1 Global Allogeneic Universal Cell Drugs Sales by Region: 2019-2024
3.2.2 Global Allogeneic Universal Cell Drugs Sales by Region: 2025-2030
3.3 Global Allogeneic Universal Cell Drugs Global Allogeneic Universal Cell Drugs Revenue by Region: 2019-2030
3.3.1 Global Allogeneic Universal Cell Drugs Revenue by Region: 2019-2024
3.3.2 Global Allogeneic Universal Cell Drugs Revenue by Region: 2025-2030
3.4 North America Allogeneic Universal Cell Drugs Market Facts & Figures by Country
3.4.1 North America Allogeneic Universal Cell Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Allogeneic Universal Cell Drugs Sales by Country (2019-2030)
3.4.3 North America Allogeneic Universal Cell Drugs Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Allogeneic Universal Cell Drugs Market Facts & Figures by Country
3.5.1 Europe Allogeneic Universal Cell Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Allogeneic Universal Cell Drugs Sales by Country (2019-2030)
3.5.3 Europe Allogeneic Universal Cell Drugs Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Netherlands
3.6 Asia Pacific Allogeneic Universal Cell Drugs Market Facts & Figures by Country
3.6.1 Asia Pacific Allogeneic Universal Cell Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Allogeneic Universal Cell Drugs Sales by Country (2019-2030)
3.6.3 Asia Pacific Allogeneic Universal Cell Drugs Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Southeast Asia
3.6.9 China Taiwan
3.6.10 Australia
3.7 Latin America Allogeneic Universal Cell Drugs Market Facts & Figures by Country
3.7.1 Latin America Allogeneic Universal Cell Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Allogeneic Universal Cell Drugs Sales by Country (2019-2030)
3.7.3 Latin America Allogeneic Universal Cell Drugs Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Allogeneic Universal Cell Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa Allogeneic Universal Cell Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Allogeneic Universal Cell Drugs Sales by Country (2019-2030)
3.8.3 Middle East and Africa Allogeneic Universal Cell Drugs Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Allogeneic Universal Cell Drugs Sales by Type (2019-2030)
4.1.1 Global Allogeneic Universal Cell Drugs Sales by Type (2019-2024)
4.1.2 Global Allogeneic Universal Cell Drugs Sales by Type (2025-2030)
4.1.3 Global Allogeneic Universal Cell Drugs Sales Market Share by Type (2019-2030)
4.2 Global Allogeneic Universal Cell Drugs Revenue by Type (2019-2030)
4.2.1 Global Allogeneic Universal Cell Drugs Revenue by Type (2019-2024)
4.2.2 Global Allogeneic Universal Cell Drugs Revenue by Type (2025-2030)
4.2.3 Global Allogeneic Universal Cell Drugs Revenue Market Share by Type (2019-2030)
4.3 Global Allogeneic Universal Cell Drugs Price by Type (2019-2030)
5 Segment by Application
5.1 Global Allogeneic Universal Cell Drugs Sales by Application (2019-2030)
5.1.1 Global Allogeneic Universal Cell Drugs Sales by Application (2019-2024)
5.1.2 Global Allogeneic Universal Cell Drugs Sales by Application (2025-2030)
5.1.3 Global Allogeneic Universal Cell Drugs Sales Market Share by Application (2019-2030)
5.2 Global Allogeneic Universal Cell Drugs Revenue by Application (2019-2030)
5.2.1 Global Allogeneic Universal Cell Drugs Revenue by Application (2019-2024)
5.2.2 Global Allogeneic Universal Cell Drugs Revenue by Application (2025-2030)
5.2.3 Global Allogeneic Universal Cell Drugs Revenue Market Share by Application (2019-2030)
5.3 Global Allogeneic Universal Cell Drugs Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Novartis
6.1.1 Novartis Corporation Information
6.1.2 Novartis Description and Business Overview
6.1.3 Novartis Allogeneic Universal Cell Drugs Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Novartis Allogeneic Universal Cell Drugs Product Portfolio
6.1.5 Novartis Recent Developments/Updates
6.2 Gilead Sciences
6.2.1 Gilead Sciences Corporation Information
6.2.2 Gilead Sciences Description and Business Overview
6.2.3 Gilead Sciences Allogeneic Universal Cell Drugs Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Gilead Sciences Allogeneic Universal Cell Drugs Product Portfolio
6.2.5 Gilead Sciences Recent Developments/Updates
6.3 Yi Zun Biology
6.3.1 Yi Zun Biology Corporation Information
6.3.2 Yi Zun Biology Description and Business Overview
6.3.3 Yi Zun Biology Allogeneic Universal Cell Drugs Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Yi Zun Biology Allogeneic Universal Cell Drugs Product Portfolio
6.3.5 Yi Zun Biology Recent Developments/Updates
6.4 Bangyao Biotechnology
6.4.1 Bangyao Biotechnology Corporation Information
6.4.2 Bangyao Biotechnology Description and Business Overview
6.4.3 Bangyao Biotechnology Allogeneic Universal Cell Drugs Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Bangyao Biotechnology Allogeneic Universal Cell Drugs Product Portfolio
6.4.5 Bangyao Biotechnology Recent Developments/Updates
6.5 Usano
6.5.1 Usano Corporation Information
6.5.2 Usano Description and Business Overview
6.5.3 Usano Allogeneic Universal Cell Drugs Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Usano Allogeneic Universal Cell Drugs Product Portfolio
6.5.5 Usano Recent Developments/Updates
6.6 Cellectis
6.6.1 Cellectis Corporation Information
6.6.2 Cellectis Description and Business Overview
6.6.3 Cellectis Allogeneic Universal Cell Drugs Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Cellectis Allogeneic Universal Cell Drugs Product Portfolio
6.6.5 Cellectis Recent Developments/Updates
6.7 Allogene
6.6.1 Allogene Corporation Information
6.6.2 Allogene Description and Business Overview
6.6.3 Allogene Allogeneic Universal Cell Drugs Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Allogene Allogeneic Universal Cell Drugs Product Portfolio
6.7.5 Allogene Recent Developments/Updates
6.8 Caribou
6.8.1 Caribou Corporation Information
6.8.2 Caribou Description and Business Overview
6.8.3 Caribou Allogeneic Universal Cell Drugs Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Caribou Allogeneic Universal Cell Drugs Product Portfolio
6.8.5 Caribou Recent Developments/Updates
6.9 Poseida Therapeutics
6.9.1 Poseida Therapeutics Corporation Information
6.9.2 Poseida Therapeutics Description and Business Overview
6.9.3 Poseida Therapeutics Allogeneic Universal Cell Drugs Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Poseida Therapeutics Allogeneic Universal Cell Drugs Product Portfolio
6.9.5 Poseida Therapeutics Recent Developments/Updates
6.10 Keji Pharmaceutical
6.10.1 Keji Pharmaceutical Corporation Information
6.10.2 Keji Pharmaceutical Description and Business Overview
6.10.3 Keji Pharmaceutical Allogeneic Universal Cell Drugs Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Keji Pharmaceutical Allogeneic Universal Cell Drugs Product Portfolio
6.10.5 Keji Pharmaceutical Recent Developments/Updates
6.11 Beiheng Biotechnology
6.11.1 Beiheng Biotechnology Corporation Information
6.11.2 Beiheng Biotechnology Allogeneic Universal Cell Drugs Description and Business Overview
6.11.3 Beiheng Biotechnology Allogeneic Universal Cell Drugs Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Beiheng Biotechnology Allogeneic Universal Cell Drugs Product Portfolio
6.11.5 Beiheng Biotechnology Recent Developments/Updates
6.12 Grace Biotechnology
6.12.1 Grace Biotechnology Corporation Information
6.12.2 Grace Biotechnology Allogeneic Universal Cell Drugs Description and Business Overview
6.12.3 Grace Biotechnology Allogeneic Universal Cell Drugs Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Grace Biotechnology Allogeneic Universal Cell Drugs Product Portfolio
6.12.5 Grace Biotechnology Recent Developments/Updates
6.13 Nkarta Therapeutic
6.13.1 Nkarta Therapeutic Corporation Information
6.13.2 Nkarta Therapeutic Allogeneic Universal Cell Drugs Description and Business Overview
6.13.3 Nkarta Therapeutic Allogeneic Universal Cell Drugs Sales, Revenue and Gross Margin (2019-2024)
6.13.4 Nkarta Therapeutic Allogeneic Universal Cell Drugs Product Portfolio
6.13.5 Nkarta Therapeutic Recent Developments/Updates
6.14 Fate Therapeutics
6.14.1 Fate Therapeutics Corporation Information
6.14.2 Fate Therapeutics Allogeneic Universal Cell Drugs Description and Business Overview
6.14.3 Fate Therapeutics Allogeneic Universal Cell Drugs Sales, Revenue and Gross Margin (2019-2024)
6.14.4 Fate Therapeutics Allogeneic Universal Cell Drugs Product Portfolio
6.14.5 Fate Therapeutics Recent Developments/Updates
6.15 Ruishun Biology
6.15.1 Ruishun Biology Corporation Information
6.15.2 Ruishun Biology Allogeneic Universal Cell Drugs Description and Business Overview
6.15.3 Ruishun Biology Allogeneic Universal Cell Drugs Sales, Revenue and Gross Margin (2019-2024)
6.15.4 Ruishun Biology Allogeneic Universal Cell Drugs Product Portfolio
6.15.5 Ruishun Biology Recent Developments/Updates
6.16 Cynata
6.16.1 Cynata Corporation Information
6.16.2 Cynata Allogeneic Universal Cell Drugs Description and Business Overview
6.16.3 Cynata Allogeneic Universal Cell Drugs Sales, Revenue and Gross Margin (2019-2024)
6.16.4 Cynata Allogeneic Universal Cell Drugs Product Portfolio
6.16.5 Cynata Recent Developments/Updates
6.17 Fate
6.17.1 Fate Corporation Information
6.17.2 Fate Allogeneic Universal Cell Drugs Description and Business Overview
6.17.3 Fate Allogeneic Universal Cell Drugs Sales, Revenue and Gross Margin (2019-2024)
6.17.4 Fate Allogeneic Universal Cell Drugs Product Portfolio
6.17.5 Fate Recent Developments/Updates
6.18 Century
6.18.1 Century Corporation Information
6.18.2 Century Allogeneic Universal Cell Drugs Description and Business Overview
6.18.3 Century Allogeneic Universal Cell Drugs Sales, Revenue and Gross Margin (2019-2024)
6.18.4 Century Allogeneic Universal Cell Drugs Product Portfolio
6.18.5 Century Recent Developments/Updates
6.19 Cytovia
6.19.1 Cytovia Corporation Information
6.19.2 Cytovia Allogeneic Universal Cell Drugs Description and Business Overview
6.19.3 Cytovia Allogeneic Universal Cell Drugs Sales, Revenue and Gross Margin (2019-2024)
6.19.4 Cytovia Allogeneic Universal Cell Drugs Product Portfolio
6.19.5 Cytovia Recent Developments/Updates
6.20 BeiGene
6.20.1 BeiGene Corporation Information
6.20.2 BeiGene Allogeneic Universal Cell Drugs Description and Business Overview
6.20.3 BeiGene Allogeneic Universal Cell Drugs Sales, Revenue and Gross Margin (2019-2024)
6.20.4 BeiGene Allogeneic Universal Cell Drugs Product Portfolio
6.20.5 BeiGene Recent Developments/Updates
6.21 Cell-Origin
6.21.1 Cell-Origin Corporation Information
6.21.2 Cell-Origin Allogeneic Universal Cell Drugs Description and Business Overview
6.21.3 Cell-Origin Allogeneic Universal Cell Drugs Sales, Revenue and Gross Margin (2019-2024)
6.21.4 Cell-Origin Allogeneic Universal Cell Drugs Product Portfolio
6.21.5 Cell-Origin Recent Developments/Updates
6.22 Neukio
6.22.1 Neukio Corporation Information
6.22.2 Neukio Allogeneic Universal Cell Drugs Description and Business Overview
6.22.3 Neukio Allogeneic Universal Cell Drugs Sales, Revenue and Gross Margin (2019-2024)
6.22.4 Neukio Allogeneic Universal Cell Drugs Product Portfolio
6.22.5 Neukio Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Allogeneic Universal Cell Drugs Industry Chain Analysis
7.2 Allogeneic Universal Cell Drugs Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Allogeneic Universal Cell Drugs Production Mode & Process
7.4 Allogeneic Universal Cell Drugs Sales and Marketing
7.4.1 Allogeneic Universal Cell Drugs Sales Channels
7.4.2 Allogeneic Universal Cell Drugs Distributors
7.5 Allogeneic Universal Cell Drugs Customers
8 Allogeneic Universal Cell Drugs Market Dynamics
8.1 Allogeneic Universal Cell Drugs Industry Trends
8.2 Allogeneic Universal Cell Drugs Market Drivers
8.3 Allogeneic Universal Cell Drugs Market Challenges
8.4 Allogeneic Universal Cell Drugs Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock